Reducing the global burden of HTLV-1 infection: An agenda for research and action - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Antiviral Research Année : 2017

Reducing the global burden of HTLV-1 infection: An agenda for research and action

Luc Willems
  • Fonction : Auteur correspondant
  • PersonId : 1048401

Connectez-vous pour contacter l'auteur
Antoine Gessain
Masao Matsuoka
Toshiki Watanabe
Yoshihisa Yamano

Résumé

Even though an estimated 10-20 million people worldwide are infected with the oncogenic retrovirus, human T-lymphotropic virus type 1 (HTLV-1), its epidemiology is poorly understood, and little effort has been made to reduce its prevalence. In response to this situation, the Global Virus Network launched a taskforce in 2014 to develop new methods of prevention and treatment of HTLV-1 infection and promote basic research. HTLV-1 is the etiological agent of two life-threatening diseases, adult T-cell leukemia and HTLV-associated myelopathy/tropical spastic paraparesis, for which no effective therapy is currently available. Although the modes of transmission of HTLV-1 resemble those of the more familiar HIV-1, routine diagnostic methods are generally unavailable to support the prevention of new infections. In the present article, the Taskforce proposes a series of actions to expand epidemiological studies; increase research on mechanisms of HTLV-1 persistence, replication and pathogenesis; discover effective treatments; and develop prophylactic and therapeutic vaccines.

Dates et versions

hal-02137848 , version 1 (23-05-2019)

Identifiants

Citer

Luc Willems, Hideki Hasegawa, Roberto Accolla, Charles Bangham, Ali Bazarbachi, et al.. Reducing the global burden of HTLV-1 infection: An agenda for research and action. Antiviral Research, 2017, 137, pp.41-48. ⟨10.1016/j.antiviral.2016.10.015⟩. ⟨hal-02137848⟩
63 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More